More than 1 in every 4,300 individuals suffer from a primary mitochondrial disease. Dysfunctional mitochondria play an integral part in many different diseases, ranging from very severe childhood diseases to more common diseases, such as age-related disorders. Inherited mitochondrial diseases, caused by genetic changes in the mtDNA, have no cure, very limited or no treatment options, and can often result in early childhood death. More common age-related disorders may be addressed by correcting the dysfunctional mitochondria. Primera is aiming to address the root cause of mitochondrial diseases with first-in-class gene editing therapeutics.